Research synthesisLow evidenceModerate effect3 studies · 2 beneficial · 1 neutral · 0 harmful
Across 3 studies, 2 reported beneficial moderate-sized effects, and 1 found a neutral small effect. Two out of 3 studies reached statistical significance. The evidence primarily comes from clinical populations, specifically children with sickle cell disease (VOE) and head and neck cancer patients with radiation-induced oral mucositis. Median study duration across the one study that reported duration was 7 weeks, suggesting effects are typically observed within that timeframe.
- Effective dose range: For sickle cell disease: 100 mg/kg/dose three times/day; for head and neck cancer: 5 g/day.
- Studied populations: Children with sickle cell disease experiencing vaso-occlusive episodes; head and neck cancer patients with radiation-induced oral mucositis.
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. The beneficial effects were observed in specific clinical populations, so generalizability to other pain conditions or healthy individuals is unknown.
Generated Jun 12, 2026